Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for the treatment of intractable diseases in the United States. The company has a wide range of products in its pipeline, including ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. In addition, Arrowhead Pharmaceuticals is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets.

The company also has several license and research collaboration agreements with various pharmaceutical companies, including Janssen Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. These collaborations are focused on the development of RNAi therapeutics for liver-expressed targets.

Founded in 1989, Arrowhead Pharmaceuticals, Inc. is headquartered in Pasadena, California. The company is publicly traded on the Nasdaq Global Select Market under the ticker symbol ARWR. As of May 2021, the company had a market capitalization of $3.8 billion and a price-to-earnings ratio of -3.46.